Efficacy and tolerability of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin
(1993) In Annals of oncology : official journal of the European Society for Medical Oncology 4(Suppl 3). p.31-34- Abstract
A multicentre study was performed at four oncology centres in Sweden, in 160 chemotherapy-naive women, primarily with ovarian or endometrial carcinomas. Abdominal surgery preceded chemotherapy in 146 (91%) women, and another 39 (24%) women had a history of radiotherapy. The chemotherapy regimens contained cisplatin (50-100 mg/m2), in combination with a variety of other agents. In Course 1, all patients received tropisetron (5 mg i.v. Day 1; 5 mg p.o. Days 2-6) and 84% of patients achieved total or partial control of vomiting; 95% of patients achieved total or partial control of nausea during the first 24 hours. Vomiting was least successfully controlled on Day 2 (73% total or partial control) and Days 2-4 for the control of nausea (81,... (More)
A multicentre study was performed at four oncology centres in Sweden, in 160 chemotherapy-naive women, primarily with ovarian or endometrial carcinomas. Abdominal surgery preceded chemotherapy in 146 (91%) women, and another 39 (24%) women had a history of radiotherapy. The chemotherapy regimens contained cisplatin (50-100 mg/m2), in combination with a variety of other agents. In Course 1, all patients received tropisetron (5 mg i.v. Day 1; 5 mg p.o. Days 2-6) and 84% of patients achieved total or partial control of vomiting; 95% of patients achieved total or partial control of nausea during the first 24 hours. Vomiting was least successfully controlled on Day 2 (73% total or partial control) and Days 2-4 for the control of nausea (81, 83, 88% total or partial control, respectively). Patients with partial response in Course 1 (39% of patients) were randomized to addition of dexamethasone or placebo in Course 2. In Course 2, tropisetron plus dexamethasone (Group B2) prevented acute vomiting in 75% of patients, compared with 40% of patients receiving tropisetron plus placebo (Group B1). Over the entire 6 days, there was no vomiting at all in 54% and 20% of B2 and B1 patients, respectively. In Course 2, acute nausea was prevented in 75% of patients (receiving B1) and in 37% of patients (receiving B2). For nausea, over the complete 6 days, the figures were 64% and 3% (p < 0.001). This indicated that patients with incomplete control of emesis in Course 1 benefited from the addition of dexamethasone, provided that it was added for each of the 6 days studied.(ABSTRACT TRUNCATED AT 250 WORDS)
(Less)
- author
- Schmidt, M ; Sorbe, B ; Högberg, T LU ; Himmelmann, A ; Räisänen, I ; Stockmeyer, M and de Bruijn, K M
- publishing date
- 1993
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Adult, Aged, Aged, 80 and over, Antiemetics/administration & dosage, Cisplatin/adverse effects, Dexamethasone/administration & dosage, Drug Therapy, Combination, Female, Humans, Indoles/administration & dosage, Middle Aged, Nausea/chemically induced, Serotonin Antagonists/administration & dosage, Tropisetron, Vomiting/chemically induced
- in
- Annals of oncology : official journal of the European Society for Medical Oncology
- volume
- 4
- issue
- Suppl 3
- pages
- 31 - 34
- publisher
- Oxford University Press
- external identifiers
-
- pmid:8363997
- scopus:0027303711
- ISSN
- 0923-7534
- DOI
- 10.1093/annonc/4.suppl_3.s31
- language
- English
- LU publication?
- no
- id
- 34c63eca-fa0a-46fa-9411-272f45cbb347
- date added to LUP
- 2019-09-20 08:15:05
- date last changed
- 2024-01-01 20:57:20
@article{34c63eca-fa0a-46fa-9411-272f45cbb347,
abstract = {{<p>A multicentre study was performed at four oncology centres in Sweden, in 160 chemotherapy-naive women, primarily with ovarian or endometrial carcinomas. Abdominal surgery preceded chemotherapy in 146 (91%) women, and another 39 (24%) women had a history of radiotherapy. The chemotherapy regimens contained cisplatin (50-100 mg/m2), in combination with a variety of other agents. In Course 1, all patients received tropisetron (5 mg i.v. Day 1; 5 mg p.o. Days 2-6) and 84% of patients achieved total or partial control of vomiting; 95% of patients achieved total or partial control of nausea during the first 24 hours. Vomiting was least successfully controlled on Day 2 (73% total or partial control) and Days 2-4 for the control of nausea (81, 83, 88% total or partial control, respectively). Patients with partial response in Course 1 (39% of patients) were randomized to addition of dexamethasone or placebo in Course 2. In Course 2, tropisetron plus dexamethasone (Group B2) prevented acute vomiting in 75% of patients, compared with 40% of patients receiving tropisetron plus placebo (Group B1). Over the entire 6 days, there was no vomiting at all in 54% and 20% of B2 and B1 patients, respectively. In Course 2, acute nausea was prevented in 75% of patients (receiving B1) and in 37% of patients (receiving B2). For nausea, over the complete 6 days, the figures were 64% and 3% (p < 0.001). This indicated that patients with incomplete control of emesis in Course 1 benefited from the addition of dexamethasone, provided that it was added for each of the 6 days studied.(ABSTRACT TRUNCATED AT 250 WORDS)</p>}},
author = {{Schmidt, M and Sorbe, B and Högberg, T and Himmelmann, A and Räisänen, I and Stockmeyer, M and de Bruijn, K M}},
issn = {{0923-7534}},
keywords = {{Adult; Aged; Aged, 80 and over; Antiemetics/administration & dosage; Cisplatin/adverse effects; Dexamethasone/administration & dosage; Drug Therapy, Combination; Female; Humans; Indoles/administration & dosage; Middle Aged; Nausea/chemically induced; Serotonin Antagonists/administration & dosage; Tropisetron; Vomiting/chemically induced}},
language = {{eng}},
number = {{Suppl 3}},
pages = {{31--34}},
publisher = {{Oxford University Press}},
series = {{Annals of oncology : official journal of the European Society for Medical Oncology}},
title = {{Efficacy and tolerability of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin}},
url = {{http://dx.doi.org/10.1093/annonc/4.suppl_3.s31}},
doi = {{10.1093/annonc/4.suppl_3.s31}},
volume = {{4}},
year = {{1993}},
}